Redwood AI’s Stock Rout Deepens as Board Resignation and Unfunded Ebola Pact Stoke Doubts

Redwood AI stock drops 26% after non-binding MoU for AI pathogen tracking in Ebola-hit region; investors doubt execution amid cash burn and board resignation.

The Ebola outbreak tearing through eastern Congo and Rwanda has claimed 136 lives among 676 confirmed cases, according to data through June 10. Redwood AI, a tiny Canadian artificial-intelligence firm, sees an opportunity to deploy its technology in the crisis zone. Investors, however, are voting with their feet — and their verdict is brutal.

Shares plunged 7.52% on Friday to C$2.95, extending the week’s slide to nearly 26%. The stock has now lost roughly 18% year-to-date from a level of C$3.19, though Friday’s close marks a fresh low. The trigger: a non-binding memorandum of understanding signed June 11 with the University of Global Health Equity in Rwanda to build a pathogen-tracking system along the border with the Democratic Republic of Congo.

The system would use AI to map infectious diseases in real time, specifically targeting the Bundibugyo ebolavirus strain that has spread across 27 health zones since emerging in Ituri province. The World Health Organization has warned that conflict, misinformation and violence are creating blind spots in traditional surveillance — exactly the gap Redwood AI aims to fill. But the MoU is legally unenforceable, with no committed financing or final contracts. Management itself describes the project as a planning phase.

Compounding the uncertainty, board member Graydon Bensler resigned with immediate effect. The company offered no explanation for his abrupt departure, leaving a director vacancy at a precarious moment for the micro-cap firm. Redwood AI holds C$2 million in cash against losses of C$11 million, underscoring the fragility of its balance sheet.

The Rwanda pledge follows a familiar pattern. In May, Redwood signed another non-binding letter of intent to acquire cybersecurity startup Quantum.IQ, a deal that could involve issuing up to 14 million new shares. Simultaneously, a subsidiary lined up potential grant funding for a chemical-screening project — again contingent on further commitments. None of these moves have produced firm revenue or binding agreements.

Investor skepticism reflects the gap between ambition and execution. While giants like Meta and Alphabet pour resources into cloud infrastructure, Redwood targets niche government and defense applications: post-quantum encryption, pathogen tracking, and chemical analysis. The Rwanda project now serves as a litmus test. If the company can demonstrate its technology works in an active outbreak, it could unlock state contracts. If not, it remains a cash-burning micro-cap with grand plans and no binding contracts to show for them. Until tangible financing, confirmed deployment sites, or signed contracts emerge, the market is likely to keep discounting the promises with every new announcement.